These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22053595)

  • 1. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.
    Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
    Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
    Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
    Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
    Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
    Near KA; Stowers AW; Jankovic D; Kaslow DC
    Infect Immun; 2002 Feb; 70(2):692-701. PubMed ID: 11796601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of antibody responses against Gnathostoma spinigerum in mice immunized with crude antigen formulated in CpG oligonucleotide and montanide ISA720.
    Intapan PM; Hirunpetcharat C; Kularbkaew C; Yutanawiboonchai W; Janwan P; Maleewong W
    Korean J Parasitol; 2013 Dec; 51(6):637-44. PubMed ID: 24516267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
    Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicles derived from plasmodium-infected red blood cells alleviate cerebral malaria in plasmodium berghei ANKA-infected C57BL/6J mice.
    Lv Y; Wu S; Nie Q; Liu S; Xu W; Chen G; Du Y; Chen J
    Int Immunopharmacol; 2024 May; 132():111982. PubMed ID: 38569430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
    Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y
    Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.
    Sakai T; Hisaeda H; Nakano Y; Zhang M; Takashima M; Ishii K; Maekawa Y; Matsumoto S; Nitta Y; Miyazaki Ji; Yamamoto S; Himeno K
    Vaccine; 2003 Mar; 21(13-14):1432-44. PubMed ID: 12615440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.
    Chawla B; Mahajan B; Oakley M; Majam VF; Belmonte A; Sedegah M; Shimp RL; Kaslow DC; Kumar S
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses.
    Savoji MA; Sereshgi MMA; Ghahari SMM; Asgarhalvaei F; Mahdavi M
    Int Immunopharmacol; 2021 Jul; 96():107599. PubMed ID: 33848910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
    Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
    Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
    Ahlborg N; Ling IT; Holder AA; Riley EM
    Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.